Met Life Investment Management, LLC Protagonist Therapeutics, Inc Transaction History
Met Life Investment Management, LLC
- $16.6 Billion
- Q2 2024
A detailed history of Met Life Investment Management, LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Met Life Investment Management, LLC holds 33,805 shares of PTGX stock, worth $1.55 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
33,805
Previous 28,596
18.22%
Holding current value
$1.55 Million
Previous $827,000
41.6%
% of portfolio
0.01%
Previous 0.01%
Shares
30 transactions
Others Institutions Holding PTGX
# of Institutions
212Shares Held
59.1MCall Options Held
19KPut Options Held
107K-
Farallon Capital Management LLC San Francisco, CA5.84MShares$268 Million0.98% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$264 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.29MShares$242 Million3.06% of portfolio
-
Bvf Inc San Francisco, CA3.32MShares$152 Million3.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$149 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.25B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...